Adam Feuerstein

Latest stories

19h
TheStreet.com
Health care sector rejoices in a $40 billion Takeover Thursdaygoing to face competition from less expensive bio-similars. Humira accounts for
Health care sector rejoices in a $40 billion Takeover Thursday
TheStreet.com / Posted 19 hours ago
going to face competition from less expensive bio-similars. Humira accounts for more than 60% of AbbVie's total revenue. Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual... Read more
1d
TheStreet.com
Vertex Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16one year ago. Vertex shares closed Wednesday at $84.50 and were down 1% to $83
Vertex Forecasts Billion-Dollar Sales for Cystic Fibrosis Drug in '16
TheStreet.com / Posted yesterday
one year ago. Vertex shares closed Wednesday at $84.50 and were down 1% to $83.40 in the after-hours trading session. Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual... Read more
4 related stories
3d
TheStreet.com
Sarepta therapeutics fda panel live blogeteplirsen, Sarepta's experimental drug for the treatment of Duchenne muscular
Sarepta therapeutics fda panel live blog
TheStreet.com / Posted 3 days ago
eteplirsen, Sarepta's experimental drug for the treatment of Duchenne muscular dystrophy. TheStreet Senior Columnist Adam Feuerstein is providing live coverage and analysis of the Sarepta FDA advisory panel as it happens near Washington,... Read more
10d
TheStreet.com
Chiasma Craters on FDA Drug Rejectionsaid he was "surprised and disappointed" by the FDA's Mycapssa rejection. "We r
Chiasma Craters on FDA Drug Rejection
TheStreet.com / Posted 10 days ago
said he was "surprised and disappointed" by the FDA's Mycapssa rejection. "We respectfully disagree," he added. Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual... Read more
17d
TheStreet.com
Endo International tumbles as Insys expects weak painkiller salesit makes little sense for Allergan to now turn around and buy Endo, which gener
Endo International tumbles as Insys expects weak painkiller sales
TheStreet.com / Posted 17 days ago
it makes little sense for Allergan to now turn around and buy Endo, which generates half its revenue from generic drugs. Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual... Read more
20d
TheStreet.com
Clovis Smart Move is to Drop Damaged Lung Cancer Drug Altogetherfrom the company's value. But Clovis has significant debt on its books, too, so
Clovis Smart Move is to Drop Damaged Lung Cancer Drug Altogether
TheStreet.com / Posted 20 days ago
from the company's value. But Clovis has significant debt on its books, too, so net cash is only around $8 per share. Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual... Read more
22d
TheStreet.com
Here's a Reason Gilead (GILDmillion upfront to buy an early-stage pipeline of liver disease drugs from priv
Here's a Reason Gilead (GILD
TheStreet.com / Posted 22 days ago
million upfront to buy an early-stage pipeline of liver disease drugs from private company Nimbus Therapeutics, TheStreet's Adam Feuerstein reported on Monday. Separately, TheStreet Ratings Team has a "Buy" rating with a score of B on the... Read more
24d
TheStreet.com
Allergan could buy these drug companies if Pfizer merger is scuttledintriguing targets. Sure, all of these deal would be expensive, but then trans
Allergan could buy these drug companies if Pfizer merger is scuttled
TheStreet.com / Posted 24 days ago
intriguing targets. Sure, all of these deal would be expensive, but then transformational acquisitions don't come cheap. Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual... Read more
2 related stories
30d
TheStreet.com
Acadia Pharma FDA Advisory Panel Live Blogto Acadia. An affirmative decision would most likely compel FDA to approve Nupl
Acadia Pharma FDA Advisory Panel Live Blog
TheStreet.com / Posted 30 days ago
to Acadia. An affirmative decision would most likely compel FDA to approve Nuplazid by its decision date of May 1. Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual... Read more
8 related stories

People in this news